drugset / Trial / NCT06385808
Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study was to evaluate the efficacy of MTBF conditioning regimen of salvageable allo-HSCT in patients with relapsed or refractory acute myeloid leukemia. The secondary purpose of the study was to observe the safety of MTBF regimen in these patients.
Timeline
- Start
- 2024-05-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 0.8 mg/kg | Intravenous |
| Subject | Fludarabine | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Mitoxantrone hydrochloride liposome | Unknown | 24 mg/m2 | Intravenous |
| Subject | Thiotepa | Other / unclassified | 5 mg/kg | Intravenous |